China Welfare Institute International Peace Maternity and Child Health Hospital and East China University of Science & Technology have jointly developed aza-phenothiazine derivatives reported to be useful for the treatment of endometrial cancer.
Leo Pharma A/S researchers have synthesized new interleukin-17 (IL-17) modulators reported to be useful for the treatment of psoriasis, psoriatic arthritis, spondyloarthritis, radiographic ankylosing spondylitis (ankylosing spondylitis) and autoimmune diseases.
Research at RIKEN has led to the identification of furanocoumarin derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of cancer and viral infections.
Phosphatidylinositol 3-kinase α (PI3Kα) inhibitors have been reported in a Synnovation Therapeutics Inc. patent as useful for the treatment of cancer, PIK3CA-related overgrowth spectrum, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Adimab LLC to discover and develop innovative antibody drugs in the oncology field.
The Global Health Innovative Technology (GHIT) Fund has announced new investments in the development of a new prophylactic vaccine against malaria, a new anti-malarial drug, and product development projects against neglected tropical diseases.
Previous research has shown high expression of angiotensin-converting enzyme 1 (ACE1) in the triple-negative breast cancer (TNBC) cell line MDA-MB-231, suggesting the potential of ACE1 as a novel target for this disease. In the current study, researchers from Peking University Cancer Hospital presented the discovery of [68Ga]DOTA-BPP, a novel peptide nuclide molecular imaging probe targeting ACE1 for the imaging of TNBC.